China-focused private equity firm ZQ Capital sold a U.S. medical device manufacturer to buyout firm GTCR for about $800 million including debt, people familiar with the matter said.
A consortium led by ZQ Capital, founded by a pair of former Barclays Plc and JPMorgan Chase & Co. bankers, and Vivo Capital, sold Surgical Specialties Corp. according to a release on Monday, which didn’t give the transaction value. A representative for ZQ Capital declined to comment on the value. A representative for GTCR did not respond to requests for comment made outside normal business hours.
Other co-investors in the original 2017 purchase of the Massachusetts-based device maker included Aretex Capital, China Orient Asset Management, Fung Shing Investment, FS KKR Capital, Cathay Venture and Nan Fung Group, the release showed.
The acquisition by the Chicago-based GTCR follows the purchase through a partnership of TachoSil Fibrin Sealant Patch, a ready-to-use surgical patch maker, from Takeda Pharmaceutical Co. in September for 350 million euros ($415 million) according to a release at the time. The sale to Corza Health Inc., a health-care focused venture which is partly owned by GTCR, is expected to close in March.
Surgical Specialties develops and produces high-performance sutures and surgical needles, according to its website. The company has manufacturing facilities in the U.S., Mexico, England, Germany and China.
Hong Kong-based ZQ Capital was founded in 2016 by Simon Shen and Helge Weiner-Trapness, formerly with Barclays and JPMorgan respectively, according to its website. The firm is focused on cross-border deals that help global companies expand in China’s market.
GTCR has invested across the health-care services and life sciences industries, according to its website. As of 2019 the firm had completed more than 90 health-care deals, including platform investments and add-on acquisitions, with over $13 billion since 2010.
Source: BNN Bloomberg
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.